Serum concentrations of asymmetric and symmetric dimethylarginine are associated with mortality in acute heart failure patients

Ines Potočnjak, Bojana Radulović, Vesna Degoricija, Matias Trbušić, Gudrun Pregartner, Andrea Berghold, Andreas Meinitzer, Saša Frank, Ines Potočnjak, Bojana Radulović, Vesna Degoricija, Matias Trbušić, Gudrun Pregartner, Andrea Berghold, Andreas Meinitzer, Saša Frank

Abstract

Background: Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine are established predictors of total and cardiovascular mortality. However, the predictive capacity of ADMA and SDMA for hospital and 3-months mortality of patients with acute heart failure (AHF) is unknown.

Methods & results: Out of 152 included AHF patients, 79 (52%) were female, and the mean patient age was 75.2 ± 10.3 years. Hospital and three-month mortality rates were 14.5% and 27.4%, respectively. Serum ADMA and SDMA levels at admission, determined by reversed phase high performance liquid chromatography, were higher in patients having at least one of the three signs implying venous volume overload (enlarged liver, ascites, peripheral edema), a consequence of right-sided heart failure, compared to patients without those signs. Univariable logistic regression analyses revealed a significant positive association of ADMA and SDMA concentrations with hospital mortality [odds ratio (OR) and 95% confidence interval (CI) per standard deviation (SD) increase: 2.22 (1.37-3.79), p = 0.002, and 2.04 (1.34-3.18), p = 0.001, respectively], and 3-months mortality [2.06 (1.36-3.26), p = 0.001, and 2.52 (1.67-4.04), p < 0.001, respectively]. These associations remained significant after adjusting for age, sex, mean arterial pressure, low-density lipoprotein cholesterol, glomerular filtration rate, and N-terminal pro-brain natriuretic peptide.

Conclusions: We conclude that ADMA and SDMA concentrations are associated with hospital and 3-month mortality and are increased by venous volume overload in AHF patients.

Keywords: ADMA; Acute heart failure; Mortality; Prognostic biomarkers; SDMA.

Conflict of interest statement

Conflict of interest

The authors report no relationships that could be construed as a conflict of interest.

Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

References

    1. Roger VL. Epidemiology of heart failure. Circ Res. 2013;113(6):646–659.
    1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, PooleWilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J. 2008;29(19):2388–2442.
    1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, GomezSanchez MA, Jaarsma T, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–1847.
    1. Liu X, Hou L, Xu D, Chen A, Yang L, Zhuang Y, Xu Y, Fassett JT, Chen Y. Effect of asymmetric dimethylarginine (ADMA) on heart failure development. Nitric Oxide. 2016;54:73–81.
    1. Tain YL, Hsu CN. Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA) Toxins (Basel) 2017;9(3)
    1. Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens. 1997;15(8):901–909.
    1. Krzyzanowska K, Mittermayer F, Shnawa N, Hofer M, Schnabler J, Etmuller Y, Kapiotis S, Wolzt M, Schernthaner G. Asymmetrical dimethylarginine is related to renal function, chronic in flammation and macroangiopathy in patients with Type 2 diabetes and albuminuria. Diabet Med. 2007;24(1):81–86.
    1. Meinitzer A, Kielstein JT, Pilz S, Drechsler C, Ritz E, Boehm BO, Winkelmann BR, Marz W. Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem. 2011;57(1):112–121.
    1. Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, Winkelmann BR, Marz W. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study) Clin Chem. 2007;53(2):273–283.
    1. Schlesinger S, Sonntag SR, Lieb W, Maas R. Asymmetric and symmetric dimethylarginine as risk markers for total mortality and cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. PLoS One. 2016;11(11):e0165811.
    1. Tang WH, Tong W, Shrestha K, Wang Z, Levison BS, Delfraino B, Hu B, Troughton RW, Klein AL, Hazen SL. Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur Heart J. 2008;29(20):2506–2513.
    1. Potocnjak I, Degoricija V, Trbusic M, Teresak SD, Radulovic B, Pregartner G, Berghold A, Tiran B, Marsche G, Frank S. Metrics of high-density lipoprotein function and hospital mortality in acute heart failure patients. PLoS One. 2016;11(6):e0157507.
    1. Radulovic B, Potocnjak I, Dokoza Teresak S, Trbusic M, Vrkic N, Malogorski D, Starcevic N, Milosevic M, Frank S, Degoricija V. Hypochloraemia as a predictor of developing hyponatraemia and poor outcome in acute heart failure patients. Int J Cardiol. 2016;212:237–241.
    1. World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194.
    1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239.
    1. Potocnjak I, Degoricija V, Trbusic M, Pregartner G, Berghold A, Marsche G, Frank S. Serum concentration of HDL particles predicts mortality in acute heart failure patients. Sci Rep. 2017;7 46642.
    1. King R, Esmail M, Mahon S, Dingley J, Dwyer S. Use of nitric oxide for decompensated right ventricular failure and circulatory shock after cardiac arrest. Br J Anaesth. 2000;85(4):628–631.
    1. Rastaldo R, Pagliaro P, Cappello S, Penna C, Mancardi D, Westerhof N, Losano G. Nitric oxide and cardiac function. Life Sci. 2007;81(10):779–793.
    1. Matter CM, Mandinov L, Kaufmann PA, Vassalli G, Jiang Z, Hess OM. Effect of NO donors on LV diastolic function in patients with severe pressure-overload hypertrophy. Circulation. 1999;99(18):2396–2401.
    1. Tomita H, Egashira K, Ohara Y, Takemoto M, Koyanagi M, Katoh M, Yamamoto H, Tamaki K, Shimokawa H, Takeshita A. Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension. 1998;32(2):273–279.
    1. Santos-Gallego CG, Badimon JJ, Rosenson RS. Beginning to understand high-density lipoproteins. Endocrinol Metab Clin N Am. 2014;43(4):913–947.
    1. Speer T, Rohrer L, Blyszczuk P, Shroff R, Kuschnerus K, Krankel N, Kania G, Zewinger S, Akhmedov A, Shi Y, Martin T, et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity. 2013;38(4):754–768.
    1. Doehner W, Frenneaux M, Anker SD. Metabolic impairment in heart failure: the myocardial and systemic perspective. J Am Coll Cardiol. 2014;64(13):1388–1400.
    1. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function–a meta-analysis. Nephrol Dial Transplant. 2006;21(9):2446–2451.
    1. Gnanaraj JF, von Haehling S, Anker SD, Raj DS, Radhakrishnan J. The relevance of congestion in the cardio-renal syndrome. Kidney Int. 2013;83(3):384–391.
    1. Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med. 2000;109(2):109–113.
    1. James WP, Hay AM. Albumin metabolism: effect of the nutritional state and the dietary protein intake. J Clin Invest. 1968;47(9):1958–1972.
    1. Rothschild MA, Oratz M, Schreiber SS. Albumin metabolism. Gastroenterology. 1973; 64(2):324–337.
    1. McFarlane AS, Todd D, Cromwell S. Fibrinogen catabolism in humans. Clin Sci. 1964;26:415–420.
    1. Marliss EB, Chevalier S, Gougeon R, Morais JA, Lamarche M, Adegoke OA, Wu G. Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia. 2006;49(2):351–359.
    1. Caglar K, Yilmaz MI, Sonmez A, Cakir E, Kaya A, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Bilgi C, Oktenli C, et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int. 2006;70(4):781–787.
    1. Chen Y, Park S, Li Y, Missov E, Hou M, Han X, Hall JL, Miller LW, Bache RJ. Alterations of gene expression in failing myocardium following left ventricular assist device support. Physiol Genomics. 2003;14(3):251–260.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir